中石化(00386.HK)成立医用卫生材料研究所
中石化(00386.HK)发布消息指,中石化所属北京化工研究院近日正式成立医用卫生材料研究所,研究所的成立,将加快中国医用卫生关键核心材料的技术开发,保障国内生物医药产业链安全,推动产业升级,助力国家医用卫生材料核心技术自立自强目标实现。
该研究所将以解决制约中国医用材料发展的瓶颈问题为导向,聚焦关键核心难题并创新科研体制机制,冀解决制约医用材料产业发展的共性关键技术,开发出一批示范性专项成套技术。下一步,医用卫生材料研究所将联合医卫行业的相关龙头企业,搭建医卫材料的全产业链协同创新产业联盟,建设中石化医用卫生材料创新研发平台,推动中石化现有医卫产品快速扩展市场。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.